Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1 | Zendy

Ka Lai Yee | Zendy; Aziz Ouerdani | Zendy; Anetta Claussen | Zendy; Rik de Greef | Zendy; Larissa Wenning | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1

Author(s) -

Ka Lai Yee,

Aziz Ouerdani,

Anetta Claussen,

Rik de Greef,

Larissa Wenning

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02502-18

Subject(s) - lamivudine , reverse transcriptase inhibitor , pharmacokinetics , population , pharmacology , tenofovir , human immunodeficiency virus (hiv) , medicine , virology , sida , virus , viral disease , hepatitis b virus , environmental health

Doravirine is a novel nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus 1 (HIV-1) infection. A population pharmacokinetic (PK) model was developed for doravirine using pooled data from densely sampled phase 1 trials and from sparsely sampled phase 2b and phase 3 trials evaluating doravirine administered orally as a single entity or as part of a fixed-dose combination of doravirine-lamivudine-tenofovir disoproxil fumarate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research